To determine the maximum tolerated dose of navelbine given by short IV infusion at weekly intervals in pediatric patients with previously treated leukemia, lymphoma, or solid tumors; to determine toxicities, pharmacokinetics, and antitumor activity of this drug within confines of Phase I study.
Showing the most recent 10 out of 1267 publications